Skip to main content
Erschienen in: Clinical Research in Cardiology 8/2015

01.08.2015 | Original Paper

Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation

verfasst von: Steffen Gloekler, Samera Shakir, Janosch Doblies, Ahmed A. Khattab, Fabien Praz, Ênio Guerios, Dezsoe Koermendy, Stefan Stortecky, Thomas Pilgrim, Lutz Buellesfeld, Peter Wenaweser, Stephan Windecker, Aris Moschovitis, Milosz Jaguszewski, Ulf Landmesser, Fabian Nietlispach, Bernhard Meier

Erschienen in: Clinical Research in Cardiology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Transcatheter left atrial appendage (LAA) occlusion has been proven to be an effective treatment for stroke prophylaxis in patients with atrial fibrillation. For this purpose, the Amplatzer cardiac plug (ACP) was introduced. Its second generation, the Amulet, was developed for easier delivery, better coverage, and reduction of complications.

Aim

To investigate the safety and efficacy of first generation versus second generation Amplatzer occluders for LAA occlusion.

Methods

Retrospective analysis of prospectively collected data from the LAA occlusion registries of the Bern and Zurich university hospitals. Comparison of the last consecutive 50 ACP cases versus the first consecutive 50 Amulet cases in patients with non-valvular atrial fibrillation. For safety, a periprocedural combined endpoint, which is composed of death, stroke, cardiac tamponade, and bailout by surgery was predefined. For efficacy, the endpoint was procedural success.

Results

There were no differences between the two groups in baseline characteristics. The percentage of associated interventions during LAA occlusion was high in (78 % with ACP vs. 70 % with Amulet p = ns). Procedural success was similar in both groups (98 vs. 94 %, p = 0.61). The combined safety endpoint for severe adverse events was reached by a similar rate of patients in both groups (6 vs. 8 %, p = 0.7). Overall complication rate was insignificantly higher in the ACP group, which was mainly driven by clinically irrelevant pericardial effusions (24 vs. 14 %, p = 0.31). Death, stroke, or tamponade were similar between the groups (0 vs. 2 %, 0 vs. 0 %, or 6 vs. 6 %, p = ns).

Conclusion

Transcatheter LAA occlusion for stroke prophylaxis in patients with atrial fibrillation can be performed with similarly high success rates with first and second generations of Amplatzer occluders. According to this early experience, the Amulet has failed to improve results of LAA occlusion. The risk for major procedural adverse events is acceptable but has to be taken into account when selecting patients for LAA occlusion, a preventive procedure.
Literatur
1.
Zurück zum Zitat Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P (2009) PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374:534–542PubMedCrossRef Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P (2009) PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374:534–542PubMedCrossRef
2.
Zurück zum Zitat Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D (2013) PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) Trial. Circulation 127:720–729PubMedCrossRef Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D (2013) PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) Trial. Circulation 127:720–729PubMedCrossRef
3.
Zurück zum Zitat Landmesser U, Holmes DR (2012) Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J 33:698–704PubMedCrossRef Landmesser U, Holmes DR (2012) Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation. Eur Heart J 33:698–704PubMedCrossRef
4.
Zurück zum Zitat Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY (2014) Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy. J Am Coll Cardiol 64:1–12PubMedCrossRef Holmes DR, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY (2014) Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy. J Am Coll Cardiol 64:1–12PubMedCrossRef
5.
Zurück zum Zitat Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D (2014) PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 312:1988–1998PubMedCrossRef Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D (2014) PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 312:1988–1998PubMedCrossRef
6.
Zurück zum Zitat Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C, Glikson M (2014) EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 16:1397–1416PubMedCrossRef Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C, Glikson M (2014) EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. Europace 16:1397–1416PubMedCrossRef
7.
Zurück zum Zitat Bernhardt P, Schmidt H, Sommer T, Lüderitz B, Omran H (2006) Atrial fibrillation—patients at high risk for cerebral embolism. Clin Res Cardiol. 95:148–153PubMedCrossRef Bernhardt P, Schmidt H, Sommer T, Lüderitz B, Omran H (2006) Atrial fibrillation—patients at high risk for cerebral embolism. Clin Res Cardiol. 95:148–153PubMedCrossRef
8.
Zurück zum Zitat Nührich JM, Kuck K, Andresen D, Steven D, Spitzer SG, Hoffmann E, Schumacher B, Eckardt L, Brachmann J, Lewalter T, Hochadel M, Senges J, Willems S, Hoffmann BA (2014) Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry. Clin Res Cardiol. doi:10.1007/s00392-014-0804-1 Nührich JM, Kuck K, Andresen D, Steven D, Spitzer SG, Hoffmann E, Schumacher B, Eckardt L, Brachmann J, Lewalter T, Hochadel M, Senges J, Willems S, Hoffmann BA (2014) Oral anticoagulation is frequently discontinued after ablation of paroxysmal atrial fibrillation despite previous stroke: data from the German Ablation Registry. Clin Res Cardiol. doi:10.​1007/​s00392-014-0804-1
9.
Zurück zum Zitat Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB (2014) Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol. doi:10.1007/s00392-014-0797-9 Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB (2014) Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol. doi:10.​1007/​s00392-014-0797-9
10.
Zurück zum Zitat Sabouret P, Depret-Bixio L, Cotte FE, Marie P, Bedira N, Blin P (2014) Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (atrial fibrillation in general practice) database. Clin Res Cardiol. 103:887–893PubMedCrossRef Sabouret P, Depret-Bixio L, Cotte FE, Marie P, Bedira N, Blin P (2014) Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (atrial fibrillation in general practice) database. Clin Res Cardiol. 103:887–893PubMedCrossRef
11.
Zurück zum Zitat Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P (2011) ATRIUM investigators. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 100:897–905PubMedCentralPubMedCrossRef Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P (2011) ATRIUM investigators. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 100:897–905PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Seivani Y, Abdel-Wahab M, Geist V, Richardt G, Sulimov DS, El-Mawardy M, Toelg R, Akin I (2013) Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol. 102:799–806PubMedCrossRef Seivani Y, Abdel-Wahab M, Geist V, Richardt G, Sulimov DS, El-Mawardy M, Toelg R, Akin I (2013) Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol. 102:799–806PubMedCrossRef
13.
Zurück zum Zitat Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R (2013) Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 102:399–412PubMedCrossRef Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R (2013) Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 102:399–412PubMedCrossRef
14.
Zurück zum Zitat Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U (2014) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol. 103:173–182PubMedCrossRef Ewen S, Rettig-Ewen V, Mahfoud F, Böhm M, Laufs U (2014) Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol. 103:173–182PubMedCrossRef
15.
Zurück zum Zitat Skeppholm M, Friberg L (2014) Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol. 103:998–1005PubMedCrossRef Skeppholm M, Friberg L (2014) Adherence to warfarin treatment among patients with atrial fibrillation. Clin Res Cardiol. 103:998–1005PubMedCrossRef
16.
Zurück zum Zitat De Backer O, Arnous S, Ihlemann N, Vejlstrup N, JÃrgensen E, Pehrson S, Krieger TD, Meier P, Søndergaard L, Franzen OW (2014) Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update. Open Heart 1:e000020PubMedCentralPubMedCrossRef De Backer O, Arnous S, Ihlemann N, Vejlstrup N, JÃrgensen E, Pehrson S, Krieger TD, Meier P, Søndergaard L, Franzen OW (2014) Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update. Open Heart 1:e000020PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Authors/Task Force members (2014) ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619 Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Authors/Task Force members (2014) ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619
18.
Zurück zum Zitat Meier B, Palacios I, Windecker S, Rotter M, Cao QL, Keane D, Ruiz CE, Hijazi ZM (2003) Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 60:417–422PubMedCrossRef Meier B, Palacios I, Windecker S, Rotter M, Cao QL, Keane D, Ruiz CE, Hijazi ZM (2003) Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 60:417–422PubMedCrossRef
19.
Zurück zum Zitat Nietlispach F, Gloekler S, Khattab A, Pilgrim T, Schmid M, Wenaweser P, Windecker S, Meier B (2012) Percutaneous left atrial appendage closure. Eur Geriatr Med. 3:308–311CrossRef Nietlispach F, Gloekler S, Khattab A, Pilgrim T, Schmid M, Wenaweser P, Windecker S, Meier B (2012) Percutaneous left atrial appendage closure. Eur Geriatr Med. 3:308–311CrossRef
20.
Zurück zum Zitat Nietlispach F, Gloekler S, Krause R, Shakir S, Schmid M, Khattab AA, Wenaweser P, Windecker S, Meier B (2013) Amplatzer left atrial appendage occlusion: single center 10-year experience. Catheter Cardiovasc Interv 82:283–289PubMedCrossRef Nietlispach F, Gloekler S, Krause R, Shakir S, Schmid M, Khattab AA, Wenaweser P, Windecker S, Meier B (2013) Amplatzer left atrial appendage occlusion: single center 10-year experience. Catheter Cardiovasc Interv 82:283–289PubMedCrossRef
21.
Zurück zum Zitat Schmid M, Gloekler S, Suguner A, Wahl A, Fischer U, Arnold M, Khattab A, Nietlispach F, Guerios E, Wenaweser M, Windecker S, Meier B (2013) Transcatheter left atrial appendage closure in patients with atrial fibrillation. Cardiovasc Med. 16:123–130 Schmid M, Gloekler S, Suguner A, Wahl A, Fischer U, Arnold M, Khattab A, Nietlispach F, Guerios E, Wenaweser M, Windecker S, Meier B (2013) Transcatheter left atrial appendage closure in patients with atrial fibrillation. Cardiovasc Med. 16:123–130
22.
Zurück zum Zitat Urena M, Rodés-Cabau J, Freixa X, Saw J, Webb JG, Freeman M, Horlick E, Osten M, Chan A, Marquis JF, Champagne J, Ibrahim R (2013) Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 62:96–102PubMedCrossRef Urena M, Rodés-Cabau J, Freixa X, Saw J, Webb JG, Freeman M, Horlick E, Osten M, Chan A, Marquis JF, Champagne J, Ibrahim R (2013) Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. J Am Coll Cardiol 62:96–102PubMedCrossRef
23.
Zurück zum Zitat Rodés-Cabau J, Champagne J, Bernier M (2010) Transcatheter closure of the left atrial appendage: initial experience with the Amplatzer cardiac plug device. Catheter Cardiovasc Interv 76:186–192PubMedCrossRef Rodés-Cabau J, Champagne J, Bernier M (2010) Transcatheter closure of the left atrial appendage: initial experience with the Amplatzer cardiac plug device. Catheter Cardiovasc Interv 76:186–192PubMedCrossRef
24.
Zurück zum Zitat Park JW, Bethencourt A, Sievert H, Santoro G, Meier B, Walsh K, Lopez-Minquez JR, Meerkin D, Valdés M, Ormerod O, Leithäuser B (2011) Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 77:700–706PubMedCrossRef Park JW, Bethencourt A, Sievert H, Santoro G, Meier B, Walsh K, Lopez-Minquez JR, Meerkin D, Valdés M, Ormerod O, Leithäuser B (2011) Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 77:700–706PubMedCrossRef
25.
Zurück zum Zitat Freixa X, Chan JL, Tzikas A, Garceau P, Basmadjian A, Ibrahim R (2013) The Amplatzer™ Cardiac Plug 2 for left atrial appendage occlusion: novel features and first-in-man experience. Eurointervention. 8:1094–1098PubMedCrossRef Freixa X, Chan JL, Tzikas A, Garceau P, Basmadjian A, Ibrahim R (2013) The Amplatzer™ Cardiac Plug 2 for left atrial appendage occlusion: novel features and first-in-man experience. Eurointervention. 8:1094–1098PubMedCrossRef
26.
Zurück zum Zitat Freixa X, Abualsaud A, Chan J, Nosair M, Tzikas A, Garceau P, Basmadjian A, Ibrahim R (2014) Left atrial appendage occlusion: initial experience with the Amplatzer™ Amulet™. Int J Cardiol 174:492–496PubMedCrossRef Freixa X, Abualsaud A, Chan J, Nosair M, Tzikas A, Garceau P, Basmadjian A, Ibrahim R (2014) Left atrial appendage occlusion: initial experience with the Amplatzer™ Amulet™. Int J Cardiol 174:492–496PubMedCrossRef
27.
Zurück zum Zitat Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870PubMedCrossRef Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870PubMedCrossRef
28.
Zurück zum Zitat Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263–272PubMedCrossRef Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 137:263–272PubMedCrossRef
29.
Zurück zum Zitat Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100PubMedCrossRef Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138:1093–1100PubMedCrossRef
30.
Zurück zum Zitat Wasmer K, Köbe J, Dechering D, Milberg P, Pott C, Vogler J, Stypmann J, Waltenberger J, Mönnig G, Breithardt G, Eckardt L (2013) CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus. Clin Res Cardiol. 102:139–144PubMedCrossRef Wasmer K, Köbe J, Dechering D, Milberg P, Pott C, Vogler J, Stypmann J, Waltenberger J, Mönnig G, Breithardt G, Eckardt L (2013) CHADS(2) and CHA(2)DS (2)-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus. Clin Res Cardiol. 102:139–144PubMedCrossRef
31.
Zurück zum Zitat Meier B (2007) Catheter-based atrial shunt occlusion, when the going gets even tougher: editorial comment to use of a straight, side-hole (SSH), delivery sheath for improved delivery of Amplatzer ASD occluder. Catheter Cardiovasc Interv 69:21–22PubMedCrossRef Meier B (2007) Catheter-based atrial shunt occlusion, when the going gets even tougher: editorial comment to use of a straight, side-hole (SSH), delivery sheath for improved delivery of Amplatzer ASD occluder. Catheter Cardiovasc Interv 69:21–22PubMedCrossRef
32.
Zurück zum Zitat Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747PubMedCrossRef Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123:2736–2747PubMedCrossRef
34.
Zurück zum Zitat Guérios EE, Schmid M, Gloekler S, Khattab AA, Wenaweser PM, Windecker S, Meier B (2012) Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation. Arq Bras Cardiol 98:528–536PubMedCrossRef Guérios EE, Schmid M, Gloekler S, Khattab AA, Wenaweser PM, Windecker S, Meier B (2012) Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation. Arq Bras Cardiol 98:528–536PubMedCrossRef
35.
Zurück zum Zitat Schroeter MR, Danner BC, Hünlich M, Schillinger W (2014) Uncommon delayed and late complications after percutaneous left atrial appendage closure with Amplatzer(®) Cardiac Plug. Clin Res Cardiol. 103:285–290PubMedCrossRef Schroeter MR, Danner BC, Hünlich M, Schillinger W (2014) Uncommon delayed and late complications after percutaneous left atrial appendage closure with Amplatzer(®) Cardiac Plug. Clin Res Cardiol. 103:285–290PubMedCrossRef
36.
Zurück zum Zitat Beigel R, Wunderlich NC, Ho SY, Arsanjani R, Siegel RJ (2014) The left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 7:1251–1265PubMedCrossRef Beigel R, Wunderlich NC, Ho SY, Arsanjani R, Siegel RJ (2014) The left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 7:1251–1265PubMedCrossRef
37.
Zurück zum Zitat Saw J, Lempereur M (2014) Percutaneous left atrial appendage closure: procedural techniques and outcomes. JACC Cardiovasc Interv. 7:1205–1220PubMedCrossRef Saw J, Lempereur M (2014) Percutaneous left atrial appendage closure: procedural techniques and outcomes. JACC Cardiovasc Interv. 7:1205–1220PubMedCrossRef
38.
Zurück zum Zitat Freixa X, Kwai Chan JL, Tzikas A, Garceau P, Basmadjian A, Ibrahim R (2013) Percutaneous closure of a very large left atrial appendage using the amplatzer amulet. Can J Cardiol 29:1329.e9–1329.e11 Freixa X, Kwai Chan JL, Tzikas A, Garceau P, Basmadjian A, Ibrahim R (2013) Percutaneous closure of a very large left atrial appendage using the amplatzer amulet. Can J Cardiol 29:1329.e9–1329.e11
Metadaten
Titel
Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation
verfasst von
Steffen Gloekler
Samera Shakir
Janosch Doblies
Ahmed A. Khattab
Fabien Praz
Ênio Guerios
Dezsoe Koermendy
Stefan Stortecky
Thomas Pilgrim
Lutz Buellesfeld
Peter Wenaweser
Stephan Windecker
Aris Moschovitis
Milosz Jaguszewski
Ulf Landmesser
Fabian Nietlispach
Bernhard Meier
Publikationsdatum
01.08.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 8/2015
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-015-0828-1

Weitere Artikel der Ausgabe 8/2015

Clinical Research in Cardiology 8/2015 Zur Ausgabe

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.